Centessa Pharmaceuticals Valuation Multiples

Centessa Pharmaceuticals Overview

About Centessa Pharmaceuticals

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

Founded

2020

HQ

Employees

77

Website

centessa.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $10M

EBITDA: ($219M)

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Centessa Pharmaceuticals Financials

Centessa Pharmaceuticals reported last 12-month revenue of $10M and negative EBITDA of ($219M).

In the same LTM period, Centessa Pharmaceuticals generated $10M in gross profit, ($219M) in EBITDA losses, and had net loss of ($208M).

Centessa Pharmaceuticals P&L

In the most recent fiscal year, Centessa Pharmaceuticals reported revenue of $15M and EBITDA of ($183M).

Centessa Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals has current market cap of $4B, and enterprise value of $4B.

Centessa Pharmaceuticals' stock price is $26.70.

Centessa Pharmaceuticals Valuation Multiples

Centessa Pharmaceuticals trades at 382.8x EV/Revenue multiple, and (17.4x) EV/EBITDA.

Centessa Pharmaceuticals Financial Valuation Multiples

As of April 9, 2026, Centessa Pharmaceuticals has market cap of $4B and EV of $4B.

Equity research analysts estimate Centessa Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Centessa Pharmaceuticals has a P/E ratio of (19.0x).

Centessa Pharmaceuticals Margins & Growth Rates

Centessa Pharmaceuticals' revenue in the last 12 month declined by (33%).

Centessa Pharmaceuticals' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $2.9M for the same period.

Centessa Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Centessa Pharmaceuticals M&A Activity

Centessa Pharmaceuticals acquired XXX companies to date.

Last acquisition by Centessa Pharmaceuticals was on XXXXXXXX, XXXXX. Centessa Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Centessa Pharmaceuticals Investment Activity

Centessa Pharmaceuticals invested in XXX companies to date.

Centessa Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Centessa Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).